Scientists define important gene interaction that drives aggressive brain cancer
Scientists at Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) have identified a novel interaction between a microRNA and a gene that could lead to new therapies for the most common and deadly form of brain tumor, malignant glioma.
Massey physicians win Best Bedside Manner Awards
VCU Massey Cancer Center physicians were recognized by the community as having the best bedside manner in the 2014 Annual Best Bedside Manner Awards presented by Our Health Richmond magazine. The public voted for medical providers in the Richmond area based on kindness, empathy and attentiveness.
Massey scientists seek to improve stem cell transplant outcomes through computer modeling of next generation sequencing data
Scientists at VCU Massey Cancer Center’s award-winning Bone Marrow Transplant (BMT) Program recently published several studies that support the possibility of using next-generation DNA sequencing and mathematical modeling to not only understand the variability observed in clinical outcomes of stem cell transplantation, but also to provide a theoretical framework to make transplantation a possibility for more patients who do not have a related donor.
The Cancer Research and Resource Center of Southern Virginia in Danville moves to new location
The Cancer Research and Resource Center of Southern Virginia in Danville has moved to a new location that is more accessible to cancer patients, survivors and their families and caregivers. After four years at the Institute for Advanced Learning and Research, the office now resides in Danville’s Main Street community at Kennedy Hall, 103 S. Main Street, formerly part of Stratford College.
Innovative approach to treating pancreatic cancer combines chemo- and immuno-therapy
VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) researchers discovered a unique approach to treating pancreatic cancer that may be potentially safe and effective. The treatment method involves immunochemotherapy – a combination of chemotherapy and immunotherapy, which uses the patient’s own immune system to help fight against disease. This pre-clinical study, led by Paul B. Fisher, M.Ph., Ph.D., and Luni Emdad, M.B.B.S., Ph.D., found that the delivery of [pIC]PEI – a combination of the already-established immune-modulating molecule, polyinosine-polycytidylic acid (pIC), with delivery molecule polyethlenimine (PEI), a polymer often used in detergents, adhesives and cosmetics – inside pancreatic cancer cells triggers cancer cell death without harming normal pancreatic cells.